PharmEasy Parent API Holdings AGM 2026: New Board, CFO

API Holdings Limited, Parent Company of PharmEasy, has announced its 7th AGM Notice. A key proposal is the amendment of the Memorandum of Association (MOA) Object Clause. The proposed change will expand the company’s business scope to include e-pharmacy, hospitals and clinics, pharmacies, diagnostics, home healthcare, healthcare products, logistics and other related healthcare services.

The amendment could allow for more flexibility for future business expansion. The change itself is not expected to have an immediate financial impact but its impact on growth and valuation will depend on execution.

TL;DR

1. The unlisted parent company of PharmEasy, Thyrocare Technologies and Docon Technologies, API Holdings Limited has issued the notice for its 7th Annual General Meeting (AGM) to be held through Video Conferencing/Other Audio-Visual Means (VC/OAVM) on Wednesday, September 30, 2026 at 4:00 p.m. 

2. The notice, issued on Sept. 7, 2026, lists 17 agenda items from routine financial approvals to a major board reshuffle, a new Group CFO appointment and a significant broadening of the company’s core business objects following its merger with subsidiary Docon Technologies.

3. While the AGM notice itself is a regulatory filing and does not use the "PharmEasy" brand name directly, API Holdings Limited (CIN: U60100MH2019PLC323444) is the legal entity that owns and operates the PharmEasy platform, along with its diagnostics arm Thyrocare and logistics subsidiary Docon Technologies.

What Does the API Holdings AGM Notice Covers 

1. Meetings Basic:

Source: API 7th AGM Meeting 2026

2.Approval of the Financial Statements

To consider and approve the audited standalone and consolidated financial statements for the financial year ended 31st March 2026 and the reports of the Board of Directors and the statutory auditors.

3.Re-appointment of Statutory Auditor

The reappointment of Price Waterhouse Chartered Accountants LLP as statutory auditors for a second five-year term will be put to shareholders for approval, with their term expiring at the end of the 12th AGM in 2031.

4.Board and Leadership Changes

This AGM brings several notable governance changes to the PharmEasy parent's board:

• Mr. Ashutosh Sharma and Mr. Shyam Powar retire by rotation and offer themselves for reappointment as Non-Executive, Non-Independent Directors.

• Mr. Ravi Rajagopal, nominated by investor CDPQ Private Equity Asia, is proposed for appointment as a Non-Executive, Non-Independent Director, replacing Mr. Dovaldas Buzinskas.

• Mr. Mayank Bajpai, nominated by TPG Growth, is proposed for appointment as a Non-Executive, Non-Independent Director, replacing Mr. Ankur Thadani.

• Mr. Alok Kumar Jagnani is proposed for appointment as Whole-Time Director and Group Chief Financial Officer for a three-year term (May 2026 to May 2029).

• Mr. Deepak Vaidya is proposed for reappointment as an Independent Director for a second five-year term (2026–2031).

• Mr. Bobby Parikh and Mrs. Archana Bhaskar are proposed as new Independent Directors for five-year terms effective September 9, 2026, each with remuneration of Rs.22,35,000 for the partial FY27 period.

• Remuneration to Outgoing Independent Directors Mr. Subramaniam Somasundaram, Mrs. Vineeta Rai and Dr. Jaydeep Tank for the period from 01.04.2026 to 08.09.2026 on a pro-rata basis.

5.Expanded Business Objects-Focus on Healthcare Ecosystem

One of the most substantive items (Item No. 17) is a special resolution to broaden the company’s Main Objects clause in its Memorandum of Association. This follows the merger of Docon Technologies Private Limited (wholly owned subsidiary) with API Holdings pursuant to the order of the National Company Law Tribunal (Mumbai Bench) dated August 31, 2026 and effective from September 3, 2026.

The restated objects clause broadens the scope of API Holdings to cover, in formal terms:

• Integrated end-to-end healthcare ecosystems, e-pharmacies, digital healthcare marketplaces connecting patients, doctors, pharmacies, hospitals, diagnostics labs, insurers.

• Hospitals, nursing homes, clinics, diagnostic laboratories, home healthcare, and wellness services.

• Manufacturing, Distribution & Trading of Pharmaceutical, Nutraceutical, Wellness, FMCG & Personal Care products.

• Supply-chain infrastructure, including warehousing, cold-chain management, and last-mile delivery.

• Healthcare-focused research, training, and advisory services.

This restated clause effectively formalises API Holdings’ move from a pure e-pharmacy parent to a broader, tech-enabled healthcare ecosystem operator-in line with PharmEasy actually expanding into diagnostics, tele-consultation and even AI-enabled physiotherapy in 2026.

Also Read: PharmEasy Reverse Merger

Why This AGM is Important for PharmEasy’s Business

The changes to the AGM notice regarding the boardroom and the expanded objects clause reflect the major developments reported in the period around API Holdings and PharmEasy through 2025 and 2026:

1. Financial Turnaround Underway:

API Holdings posted a turnaround in its financials with FY25 revenue up 4% at Rs.5,980 crore, while net losses narrowed 38% to Rs.1,572 crore from Rs.2,534 crore a year ago. The group under CEO Rahul Guha turned EBITDA positive (ex-ESOP) in H1 FY26 and is targeting full profitability (ex-Thyrocare) by March 2027.

2. Debt reduction: 

API Holdings became debt-free in August 2026, when it repaid Rs.1,050 crore, partly by selling a 9.9% stake in Thyrocare, leaving it with around 51.02% stake. It was followed by issuance of Rs.1,700 crore NCD against pledged Thyrocare shares in September 2025.

3.IPO Plans Revised:

API Holdings, which had put its initial IPO plans on hold in 2022, is again looking at going public, reports in mid-2026 say. The company has not confirmed any current IPO plans.

4.Investor-backed governance: 

The new board nominees are from CDPQ and TPG Growth and reflect the influence of API Holdings’ institutional backers, including Prosus, Temasek, TPG Growth, CDPQ and Ranjan Pai’s MEMG family office, which is now one of the largest shareholders, with over 12% stake.

5.Business diversification: 

PharmEasy has diversified well beyond medicine delivery to diagnostics, tele-consultations, elder care, nursing services and AI-based physiotherapy, reflecting the broadened objects clause being approved at this AGM.

Conclusion

This API 7th AGM 2026 is a strategic governance change for API Holdings that strengthens its Board and formalises the evolution of API Holdings as an integrated healthcare ecosystem. The developments are in line with PharmEasy’s ongoing turnaround and debt free status in 2026.

FAQ

Is PharmEasy named in the AGM notice?

Nope. This document is registered in the name of legal entity “API Holdings Limited” parent company owning and operating PharmEasy brand, Thyrocare Technologies and Docon Technologies.

When and how will the API Holdings AGM be held?

The 7th AGM will be held on 30th September, 2026 at 4.00 p.m. IST through Video Conferencing/ Other Audio Visual Means (VC/OAVM) and the registered office situated at Navi Mumbai shall be deemed to be the venue of the meeting.

Who are the new directors being appointed at this AGM?

Mr. Ravi Rajagopal (CDPQ nominee) and Mr. Mayank Bajpai (TPG Growth nominee) are proposed as Non-Executive, Non-Independent Directors. The Board recommends appointment of Mr. Bobby Parikh and Mrs. Archana Bhaskar as Independent Directors and Mr. Alok Kumar Jagnani as Whole-Time Director and Group CFO.

Is API Holdings (PharmEasy) planning an IPO?

API Holdings is reportedly reviving plans to explore a public listing. The company had initially attempted to go public in 2022 but those plans were scrapped. The company has stated publicly that it has no such plans under formal consideration currently.

How can shareholders vote at the AGM?

The Shareholders (holders of Equity Shares, CCPS-A or CCPS-B) can vote either through a remote e-voting facility of CDSL from September 27 to September 29, 2026 or through e-voting at the time of the live AGM on September 30, 2026. Because the meeting is being conducted by VC/OAVM, proxy appointments are not permitted.

What is API Holdings' current financial position?

API Holdings posts FY25 consolidated revenue of Rs.5,980 crore, net loss narrows 38% to Rs. 1,572 crore In August 2026 the company became debt free by repaying Rs.1,050 crore partly through selling a stake in Thyrocare.